Enveda raises $311M at $2B valuation for nature-derived AI drugs
TechCrunch AI · rss · 2026-09-24
AI biotech Enveda has raised $311M at a $2 billion valuation to push more nature-derived AI-discovered drugs into clinical trials. Its pipeline includes treatments for skin conditions and drugs to preserve weight loss after stopping GLP-1s.
More from Venture
- Thrive tops evidence ranking; rollup thesis: buy companies, turn them into RL environments — curious_vii · 2026-09-24
- Best AI-rollup targets sit on high-entropy info streams you must own — curious_vii · 2026-09-24
- treg.to skill taps 60 data providers for agent lead enrichment: 20 verified emails for $0.58 — rohanpaul_ai · 2026-09-24
- SpaceX faces ~60M shares of selling pressure as 328M shares unlock — JOBhakdi · 2026-09-24
- MongoDB 3.0: a decade of sales-led growth gets rebuilt — thedealdirector · 2026-09-24
- Databricks tops $4B revenue run-rate, AI products pass $1B — thedealdirector · 2026-09-24